Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2018

June 2018 | 50 pages | ID: H9F4699308DEN
Global Markets Direct

Abstracts

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2018, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.

Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
• The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia In Chronic Kidney Disease - Overview
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
Ardelyx Inc
Daiichi Sankyo Co Ltd
Medice Arzneimittel Putter GmbH & Co KG
OPKO Health Inc
PDX Pharmaceuticals LLC
Shield Therapeutics Plc
Spectrum Pharmaceuticals Inc
Hyperphosphatemia In Chronic Kidney Disease - Drug Profiles
CGN-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-2330 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fermagate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
niacinamide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PDX-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PT-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Hyperphosphatemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPI-014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VS-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Apr 18, 2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings
Jan 06, 2017: Shield Therapeutics Provides Update on PT20
May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
Jan 07, 2013: Spectrum Pharma Announces Positive RenaZorb Phase I Clinical Data Demonstrating Robust Activity In Easy-to-swallow Pill Formulation
May 29, 2012: Spectrum Pharma Announces Enrollment Of First Group Of Patients In Phase I Clinical Trial Of RenaZorb
Dec 05, 2011: Spectrum Pharmaceuticals Files Investigational New Drug Application With FDA For SPI-014
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Medice Arzneimittel Putter GmbH & Co KG, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by PDX Pharmaceuticals LLC, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Spectrum Pharmaceuticals Inc, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H1 2018
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Ardelyx Inc
Daiichi Sankyo Co Ltd
Medice Arzneimittel Putter GmbH & Co KG
OPKO Health Inc
PDX Pharmaceuticals LLC
Shield Therapeutics Plc
Spectrum Pharmaceuticals Inc